Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This clinical trial compares the use of moxifloxacin versus ceftriaxone in the treatment of
primary pyogenic liver abscess. The trial will include nonpregnant adults presenting with
primary liver abscess based on clinical diagnosis and computed tomography. The trial aims to
determine whether the use of moxifloxacin can effectively treat primary pyogenic liver
abscess and shorten hospitalization. This regimen has the additional benefit of avoiding
nephrotoxic agents, such as aminoglycosides, used frequently in treatment of pyogenic liver
abscess. Development of antibiotic resistance to colonized bacteria in the gastrointestinal
tract will also be evaluated using stool cultures.
Phase:
Phase 4
Details
Lead Sponsor:
Kaohsiung Veterans General Hospital.
Collaborator:
Bayer
Treatments:
Ceftriaxone Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination